No Data
Hong Kong stocks movement | BEIGENE (06160) opened nearly 7% higher as the second indication for the BCL2 inhibitor, lotocilimab, was accepted for listing in China.
BEIGENE (06160) opened nearly 7% higher, and as of the time of writing, it has risen by 6.89%, trading at 136.6 Hong Kong dollars, with a transaction value of 58.3555 million Hong Kong dollars.
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs
BEIGENE (06160) issued 2.0648 million ordinary shares on May 9 due to the exercise of stock options.
BEIGENE (06160) announced that on May 9, 2025, it will issue 206 ordinary shares due to the exercise of stock options...
Results: BeiGene, Ltd. Confounded Analyst Expectations With A Surprise Profit
RBC Capital Maintains Outperform on BeiGene, Lowers Price Target to $311
BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...
